CONMED Corporation (CNMD) 10-Year Financial Performance & Capital Metrics

CNMD • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

AboutCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.Show more

Revenue $1.31B +5.0%
EBITDA $272M +41.4%
Net Income $132M +105.4%
EPS (Diluted) 4.26 +108.8%
Gross Margin 56.08% +3.2%
EBITDA Margin 20.82% +34.7%
Operating Margin 15.33% +58.2%
Net Margin 10.13% +95.6%
ROE 14.74% +80.6%
ROIC 8.24% +62.8%
Debt/Equity 0.94 -20.8%
Interest Coverage 5.37 +77.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 35.8%
✓Strong Piotroski F-Score: 9/9
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak 3Y average ROE of 4.1%
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.93%

5Y6.47%

3Y8.95%

TTM4.61%

Profit (Net Income) CAGR

10Y15.19%

5Y35.85%

3Y28.41%

TTM-51.37%

EPS CAGR

10Y13.89%

5Y34.44%

3Y29.98%

TTM-51.31%

ROCE

10Y Avg5.39%

5Y Avg5.97%

3Y Avg6.65%

Latest9.97%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	136.07B	355.82	45.85	10.23%	12.07%	13.51%	2.56%	0.68
SNNSmith & Nephew plc	13.54B	31.90	33.94	4.7%	6.88%	14.44%	4.48%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.51B	88.34	19.94	3.85%	10.05%	6.31%	6.53%	0.50
CNMDCONMED Corporation	1.24B	40.03	9.40	5%	4.75%	6.35%	12.41%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	12.57M	0.69	-0.21	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.72M	9.55	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	245.02M	28.57	-4.06	59.99%	-17.06%		0.8%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	719.17M	763.52M	796.39M	859.63M	955.1M	862.46M	1.01B	1.05B	1.24B	1.31B
Revenue Growth %	-0.02%	0.06%	0.04%	0.08%	0.11%	-0.1%	0.17%	0.03%	0.19%	0.05%
Cost of Goods Sold+	337.47M	355.19M	365.35M	390.52M	430.38M	402.16M	442.6M	474.23M	568.5M	573.98M
COGS % of Revenue	0.47%	0.47%	0.46%	0.45%	0.45%	0.47%	0.44%	0.45%	0.46%	0.44%
Gross Profit+	381.7M	408.33M	431.04M	469.11M	524.72M	460.3M	568.04M	571.25M	676.25M	733.03M
Gross Margin %	0.53%	0.53%	0.54%	0.55%	0.55%	0.53%	0.56%	0.55%	0.54%	0.56%
Gross Profit Growth %	-0.04%	0.07%	0.06%	0.09%	0.12%	-0.12%	0.23%	0.01%	0.18%	0.08%
Operating Expenses+	330.53M	370.65M	384.11M	397.81M	445.6M	414.29M	458.32M	501.19M	555.64M	532.71M
OpEx % of Revenue	0.46%	0.49%	0.48%	0.46%	0.47%	0.48%	0.45%	0.48%	0.45%	0.41%
Selling, General & Admin	303.09M	338.4M	351.8M	355.62M	400.14M	373.82M	414.75M	454.04M	503.04M	478.28M
SG&A % of Revenue	0.42%	0.44%	0.44%	0.41%	0.42%	0.43%	0.41%	0.43%	0.4%	0.37%
Research & Development	27.44M	32.25M	32.31M	42.19M	45.46M	40.47M	43.56M	47.15M	52.6M	54.43M
R&D % of Revenue	0.04%	0.04%	0.04%	0.05%	0.05%	0.05%	0.04%	0.05%	0.04%	0.04%
Other Operating Expenses	0	-2.94M	0	0	0	0	0	0	0	0
Operating Income+	51.17M	37.68M	46.94M	71.31M	79.11M	46.01M	109.72M	70.05M	120.6M	200.33M
Operating Margin %	0.07%	0.05%	0.06%	0.08%	0.08%	0.05%	0.11%	0.07%	0.1%	0.15%
Operating Income Growth %	-0.03%	-0.26%	0.25%	0.52%	0.11%	-0.42%	1.38%	-0.36%	0.72%	0.66%
EBITDA+	95.05M	92.98M	105.48M	133.11M	151.44M	118.64M	180.46M	119.81M	192.48M	272.18M
EBITDA Margin %	0.13%	0.12%	0.13%	0.15%	0.16%	0.14%	0.18%	0.11%	0.15%	0.21%
EBITDA Growth %	-0.04%	-0.02%	0.13%	0.26%	0.14%	-0.22%	0.52%	-0.34%	0.61%	0.41%
D&A (Non-Cash Add-back)	43.88M	55.31M	58.55M	61.8M	72.32M	72.63M	70.74M	49.76M	71.87M	71.86M
EBIT	51.17M	34.73M	46.94M	71.31M	73.93M	45.66M	108.59M	-41.96M	120.6M	200.33M
Net Interest Income+	-6.03M	-15.36M	-18.2M	-20.65M	-42.7M	-44.05M	-35.48M	-28.91M	-39.77M	-37.3M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	6.03M	15.36M	18.2M	20.65M	42.7M	44.05M	35.48M	28.91M	39.77M	37.3M
Other Income/Expense	-6.03M	-18.3M	-18.2M	-20.65M	-47.89M	-44.41M	-36.61M	-140.92M	-39.77M	-37.3M
Pretax Income+	45.14M	19.38M	28.73M	50.65M	31.23M	1.6M	73.11M	-70.86M	80.83M	163.03M
Pretax Margin %	0.06%	0.03%	0.04%	0.06%	0.03%	0%	0.07%	-0.07%	0.06%	0.12%
Income Tax+	14.65M	4.71M	-26.75M	9.8M	2.6M	-7.91M	10.56M	9.72M	16.37M	30.61M
Effective Tax Rate %	0.68%	0.76%	1.93%	0.81%	0.92%	5.94%	0.86%	1.14%	0.8%	0.81%
Net Income+	30.5M	14.66M	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M
Net Margin %	0.04%	0.02%	0.07%	0.05%	0.03%	0.01%	0.06%	-0.08%	0.05%	0.1%
Net Income Growth %	-0.05%	-0.52%	2.78%	-0.26%	-0.3%	-0.67%	5.57%	-2.29%	1.8%	1.05%
Net Income (Continuing)	30.5M	14.66M	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.09	0.52	1.97	1.41	0.97	0.32	1.94	-2.68	2.04	4.26
EPS Growth %	-0.06%	-0.52%	2.79%	-0.28%	-0.31%	-0.67%	5.06%	-2.38%	1.76%	1.09%
EPS (Basic)	1.10	0.53	1.99	1.45	1.01	0.33	2.14	-2.68	2.10	4.29
Diluted Shares Outstanding	27.86M	27.96M	28.17M	28.89M	29.5M	29.46M	32.22M	30.04M	31.55M	31.11M
Basic Shares Outstanding	27.65M	27.8M	27.94M	28.12M	28.32M	28.58M	29.16M	30.04M	30.67M	30.85M
Dividend Payout Ratio	0.72%	1.51%	0.4%	0.55%	0.79%	2.4%	0.37%	-	0.38%	0.19%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	404.39M	330.51M	356.78M	374.35M	397.36M	416.65M	460.12M	581.23M	615.65M	640.01M
Cash & Short-Term Investments	72.5M	27.43M	32.62M	17.51M	25.86M	27.36M	20.85M	28.94M	24.3M	24.46M
Cash Only	72.5M	27.43M	32.62M	17.51M	25.86M	27.36M	20.85M	28.94M	24.3M	24.46M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	133.86M	148.24M	167.04M	181.55M	189.1M	177.15M	183.88M	191.34M	242.28M	237.73M
Days Sales Outstanding	67.94	70.87	76.56	77.09	72.27	74.97	66.41	66.8	71.04	66.39
Inventory	166.89M	135.87M	141.44M	154.6M	164.62M	194.87M	231.64M	332.32M	318.32M	346.72M
Days Inventory Outstanding	180.51	139.62	141.3	144.49	139.61	176.86	191.03	255.78	204.38	220.48
Other Current Assets	1.87M	0	0	5.39M	0	0	0	28.62M	30.75M	31.1M
Total Non-Current Assets+	708.55M	998.47M	1B	994.79M	1.38B	1.34B	1.31B	1.72B	1.68B	1.67B
Property, Plant & Equipment	128.55M	122.03M	116.23M	113.25M	118.88M	111.41M	108.86M	115.61M	120.72M	115.79M
Fixed Asset Turnover	5.59x	6.26x	6.85x	7.59x	8.03x	7.74x	9.28x	9.04x	10.31x	11.29x
Goodwill	260.65M	397.66M	401.95M	400.44M	618.04M	618.44M	617.53M	815.43M	806.84M	805.36M
Intangible Assets	308.17M	419.55M	414.94M	413.19M	532.8M	501.54M	471.05M	681.8M	649.48M	617.66M
Long-Term Investments	-1.33M	-3.71M	0	0	0	0	0	0	0	0
Other Non-Current Assets	11.18M	59.23M	63.33M	62.75M	102.35M	96.79M	98.8M	93.88M	96.11M	116.36M
Total Assets+	1.11B	1.33B	1.36B	1.37B	1.78B	1.75B	1.77B	2.3B	2.3B	2.31B
Asset Turnover	0.65x	0.57x	0.59x	0.63x	0.54x	0.49x	0.57x	0.46x	0.54x	0.57x
Asset Growth %	0.01%	0.19%	0.02%	0.01%	0.3%	-0.01%	0.01%	0.3%	0%	0%
Total Current Liabilities+	119.72M	113.95M	150M	160.94M	188.09M	190.2M	196.65M	296.55M	310.73M	278.13M
Accounts Payable	34.72M	41.65M	42.04M	53.5M	55.97M	53.31M	58.2M	73.39M	88.22M	102.25M
Days Payables Outstanding	37.55	42.8	42	50	47.47	48.38	47.99	56.49	56.64	65.02
Short-Term Debt	1.34M	10.2M	14.7M	18.34M	13.25M	18.41M	12.25M	69.75M	0	715K
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	51.84M	30.07M	59M	46.19M	111.25M	110.81M	126.2M	153.41M	144.22M	175.17M
Current Ratio	3.38x	2.90x	2.38x	2.33x	2.11x	2.19x	2.34x	1.96x	1.98x	2.30x
Quick Ratio	1.98x	1.71x	1.44x	1.37x	1.24x	1.17x	1.16x	0.84x	0.96x	1.05x
Cash Conversion Cycle	210.9	167.69	175.85	171.58	164.41	203.45	209.45	266.09	218.78	221.85
Total Non-Current Liabilities+	408.15M	634.46M	576.53M	545.92M	876.54M	852.43M	783.94M	1.26B	1.16B	1.07B
Long-Term Debt	269.47M	488.29M	471.74M	438.56M	754.72M	735.22M	672.41M	985.08M	971.48M	905.07M
Capital Lease Obligations	0	0	0	0	17.59M	15.15M	0	0	11.55M	0
Deferred Tax Liabilities	114.62M	119.14M	77.67M	81.06M	74.49M	57.88M	68.54M	66.72M	60.9M	74.08M
Other Non-Current Liabilities	138.68M	27.02M	27.11M	26.3M	29.75M	44.19M	42.99M	203.69M	111.13M	86.29M
Total Liabilities	527.87M	748.41M	726.53M	706.87M	1.06B	1.04B	980.58M	1.55B	1.47B	1.34B
Total Debt+	269.47M	488.29M	486.44M	456.9M	793.17M	776.45M	684.66M	1.05B	991.25M	905.78M
Net Debt	196.97M	460.86M	453.82M	439.39M	767.32M	749.09M	663.81M	1.03B	966.96M	881.32M
Debt / Equity	0.46x	0.84x	0.77x	0.69x	1.12x	1.10x	0.87x	1.41x	1.19x	0.94x
Debt / EBITDA	2.83x	5.25x	4.61x	3.43x	5.24x	6.54x	3.79x	8.80x	5.15x	3.33x
Net Debt / EBITDA	2.07x	4.96x	4.30x	3.30x	5.07x	6.31x	3.68x	8.56x	5.02x	3.24x
Interest Coverage	8.49x	2.45x	2.58x	3.45x	1.85x	1.04x	3.09x	2.42x	3.03x	5.37x
Total Equity+	585.07M	580.58M	631.43M	662.27M	710.47M	709.04M	785.43M	745.54M	834.22M	962.68M
Equity Growth %	0.01%	-0.01%	0.09%	0.05%	0.07%	-0%	0.11%	-0.05%	0.12%	0.15%
Book Value per Share	21.00	20.76	22.41	22.92	24.09	24.06	24.38	24.82	26.44	30.94
Total Shareholders' Equity	585.07M	580.58M	631.43M	662.27M	710.47M	709.04M	785.43M	745.54M	834.22M	962.68M
Common Stock	313K	313K	313K	313K	313K	313K	313K	313K	313K	313K
Retained Earnings	414.51M	406.93M	440.08M	464.85M	470.84M	457.42M	496.61M	412.63M	452.53M	560.28M
Treasury Stock	-100.77M	-97.42M	-93.68M	-88.89M	-80.74M	-67.64M	-54.05M	-22.78M	-14.99M	-15.63M
Accumulated OCI	-53.89M	-58.53M	-49.08M	-55.74M	-59.28M	-63.68M	-54.2M	-57.86M	-50.17M	-58.86M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	48.07M	38.22M	65.57M	74.7M	95.13M	64.53M	111.77M	33.37M	125.35M	166.97M
Operating CF Margin %	0.07%	0.05%	0.08%	0.09%	0.1%	0.07%	0.11%	0.03%	0.1%	0.13%
Operating CF Growth %	-0.26%	-0.2%	0.72%	0.14%	0.27%	-0.32%	0.73%	-0.7%	2.76%	0.33%
Net Income	30.5M	14.66M	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M
Depreciation & Amortization	43.88M	55.31M	58.55M	61.8M	72.32M	72.63M	70.74M	69.52M	51.4M	51.3M
Stock-Based Compensation	7.5M	8.38M	8.47M	10.04M	11.78M	13.11M	16.34M	21.73M	24.26M	25.56M
Deferred Taxes	2.25M	-2.87M	-40.02M	2.06M	-6.31M	-14.23M	3M	-6.04M	700K	12.2M
Other Non-Cash Items	12.28M	118.26M	143.41M	4.21M	12.37M	13.41M	14.84M	119.44M	24.11M	-14.8M
Working Capital Changes	-36.06M	-37.26M	-16.92M	-44.27M	-23.65M	-29.9M	-55.7M	-90.7M	-39.58M	-39.72M
Change in Receivables	-9.64M	-6.38M	-13.63M	-17.46M	-13.94M	13.92M	-9.16M	-5.2M	-47.07M	-1.62M
Change in Inventory	-34.54M	3.1M	-3.93M	-15.04M	-117K	-30.4M	-37.81M	-78.56M	14.07M	-31.63M
Change in Payables	11.51M	2.09M	-286K	12.11M	38K	-2.98M	4.89M	13.3M	14.85M	14.71M
Cash from Investing+	-24.36M	-266.02M	-29.05M	-16.51M	-387.66M	-13.64M	-14.87M	-249.53M	-20.03M	-13.08M
Capital Expenditures	-15.01M	-14.75M	-12.84M	-16.51M	-20.07M	-13.01M	-14.87M	-21.79M	-19.03M	-13.08M
CapEx % of Revenue	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.01%	0.02%	0.02%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	5.18M	0	0	0	3.23M	0	0	-1M	0
Cash from Financing+	-9.77M	184.2M	-34.88M	-72.27M	300.88M	-52.06M	-101.55M	225M	-110.43M	-151M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-22.11M	-22.21M	-22.31M	-22.44M	-22.6M	-22.82M	-23.26M	-23.96M	-24.5M	-24.65M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-17.11M	-22.81M	-372K	-20.12M	-39.37M	162K	2.95M	-113.06M	2.07M	-54.35M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	33.06M	23.47M	52.72M	58.19M	75.07M	51.52M	96.9M	11.58M	106.32M	153.88M
FCF Margin %	0.05%	0.03%	0.07%	0.07%	0.08%	0.06%	0.1%	0.01%	0.09%	0.12%
FCF Growth %	-0.34%	-0.29%	1.25%	0.1%	0.29%	-0.31%	0.88%	-0.88%	8.18%	0.45%
FCF per Share	1.19	0.84	1.87	2.01	2.55	1.75	3.01	0.39	3.37	4.95
FCF Conversion (FCF/Net Income)	1.58x	2.61x	1.18x	1.83x	3.32x	6.78x	1.79x	-0.41x	1.94x	1.26x
Interest Paid	5.43M	13.76M	16.16M	19.66M	27.27M	30.45M	21.8M	26.08M	33.69M	32.65M
Taxes Paid	10.26M	9.59M	8.87M	11.05M	10.58M	9.12M	8.56M	9.07M	19.88M	15.22M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.23%	2.52%	9.16%	6.32%	4.17%	1.34%	8.37%	-10.53%	8.16%	14.74%
Return on Invested Capital (ROIC)	4.99%	3.1%	3.31%	4.89%	4.6%	2.35%	5.66%	3.26%	5.06%	8.24%
Gross Margin	53.08%	53.48%	54.12%	54.57%	54.94%	53.37%	56.21%	54.64%	54.33%	56.08%
Net Margin	4.24%	1.92%	6.97%	4.75%	3%	1.1%	6.19%	-7.71%	5.18%	10.13%
Debt / Equity	0.46x	0.84x	0.77x	0.69x	1.12x	1.10x	0.87x	1.41x	1.19x	0.94x
Interest Coverage	8.49x	2.45x	2.58x	3.45x	1.85x	1.04x	3.09x	2.42x	3.03x	5.37x
FCF Conversion	1.58x	2.61x	1.18x	1.83x	3.32x	6.78x	1.79x	-0.41x	1.94x	1.26x
Revenue Growth	-2.08%	6.17%	4.31%	7.94%	11.11%	-9.7%	17.18%	3.45%	19.06%	5%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
General Surgery	274.19M	341.42M	367.45M	-	-	-	572.21M	583.94M	711.59M	763.03M
General Surgery Growth	-	24.52%	7.62%	-	-	-	-	2.05%	21.86%	7.23%
Orthopedic Surgery	388.95M	370.47M	428.94M	-	-	-	438.42M	461.53M	533.16M	543.99M
Orthopedic Surgery Growth	-	-4.75%	15.78%	-	-	-	-	5.27%	15.52%	2.03%
Surgical Visualization	56.03M	51.63M	-	-	-	-	-	-	-	-
Surgical Visualization Growth	-	-7.85%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	361.45M	399.11M	411.04M	172.46M	179.42M	482.06M	552.53M	578.95M	700.16M	748.22M
UNITED STATES Growth	-	10.42%	2.99%	-58.04%	4.03%	168.68%	14.62%	4.78%	20.94%	6.86%
EMEA	-	147.99M	155.85M	113M	118.3M	161.08M	189.69M	197.94M	226.25M	243.06M
EMEA Growth	-	-	5.31%	-27.50%	4.69%	36.16%	17.76%	4.34%	14.31%	7.43%
Asia Pacific	-	128.9M	138.33M	94.75M	101.33M	140.6M	171.22M	162.48M	197.4M	194.68M
Asia Pacific Growth	-	-	7.32%	-31.51%	6.95%	38.75%	21.78%	-5.11%	21.49%	-1.38%
Americas (excluding the United States)	-	87.53M	91.17M	66.52M	64.27M	78.71M	97.19M	106.11M	120.93M	121.04M
Americas (excluding the United States) Growth	-	-	4.16%	-27.04%	-3.38%	22.48%	23.47%	9.17%	13.97%	0.09%
All Other Countries	201.76M	-	-	-	-	-	-	-	-	-
All Other Countries Growth	-	-	-	-	-	-	-	-	-	-
CANADA	57.63M	-	-	-	-	-	-	-	-	-
CANADA Growth	-	-	-	-	-	-	-	-	-	-
JAPAN	37.81M	-	-	-	-	-	-	-	-	-
JAPAN Growth	-	-	-	-	-	-	-	-	-	-
AUSTRALIA	33.81M	-	-	-	-	-	-	-	-	-
AUSTRALIA Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

CONMED Corporation (CNMD) has a price-to-earnings (P/E) ratio of 9.4x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

CONMED Corporation (CNMD) reported $1.35B in revenue for fiscal year 2024. This represents a 86% increase from $725.1M in 2011.

CONMED Corporation (CNMD) grew revenue by 5.0% over the past year. This is steady growth.

Yes, CONMED Corporation (CNMD) is profitable, generating $64.1M in net income for fiscal year 2024 (10.1% net margin).

Dividend & Returns

Yes, CONMED Corporation (CNMD) pays a dividend with a yield of 1.98%. This makes it attractive for income-focused investors.

CONMED Corporation (CNMD) has a return on equity (ROE) of 14.7%. This is reasonable for most industries.

CONMED Corporation (CNMD) generated $149.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...